News >

FDA Approves Pembrolizumab for Metastatic SCLC

Gina Columbus @ginacolumbusonc
Published: Tuesday, Jun 18, 2019

The FDA has granted an accelerated approval to single-agent pembrolizumab (Keytruda) for the treatment of patients with metastatic small cell lung cancer (SCLC) who have disease progression on or after platinum-based chemotherapy and ≥1 other prior line of therapy.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication